Deprecated: Creation of dynamic property cls_session::$session_data_table is deprecated in /www/sites/www.188bio.com/index/systems/cls_session.php on line 49
LKT/CEDIRANIB/C1613/25 mg188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

LKT/CEDIRANIB/C1613/25 mg

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References

Description

Cediranib is a pan-VEGFR inhibitor that displays anticancer chemotherapeutic and anti-angiogenic activities. Cediranib is currently in clinical trials and displays activity against a wide variety of cancers. In an animal model of intestinal cancer, cediranib decreases lesion number and polyp size, and in a separate animal model of brain metastasis, cediranib decreases tumor vascular bed volume.

Product Info

Cas No.

288383-20-0

Purity

≥98%

Formula

C25H27FN4O3

Formula Wt.

450.51

IUPAC Name

4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline

Synonym

AZD2171

Solubility

DMSO to 90 mg/ml

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

Info Sheet

C1613 Info Sheet PDF

References

Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013 Jun 20;31(18):2296-302. PMID: 23630200.

JuanYin J, Tracy K, Zhang L, et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis. 2009;26(5):403-14. PMID: 19277878.

Goodlad RA, Ryan AJ, Wedge SR, et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis. 2006 Oct;27(10):2133-9. PMID: 16782971.

新闻动态
行业前沿
技术文章
最新产品